SCHEMBL6887091

SCHEMBL6887091

Cc1ccc(C=C2SC(=S)N(C(CC(=O)O)C(=O)O)C2=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.74
PLA2G1B P04054 1/20 0.74
POLB P06746 1/20 0.74
ATG4B Q9Y4P1 1/20 0.74
BCL2 P10415 8/20 0.64
BCL2L2 Q92843 5/20 0.64
BAD Q92934 3/20 0.59
MME P08473 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
ALDH1A1 P00352 1/20 0.59
CRHBP P24387 1/20 0.59
CRHR2 Q13324 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
PTPN1 P18031 3/20 0.58
MAP3K5 Q99683 3/20 0.56
BCL2L1 Q07817 2/20 0.56
MCL1 Q07820 2/20 0.56
BAK1 Q16611 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887088 1.00 MAPT (0.74) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6887547 0.89 MAPT (0.76) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6887541 0.89 MAPT (0.76) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6884113 0.87 MAPT (0.70) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6884114 0.87 MAPT (0.70) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6884229 0.87 MAPT (0.60) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6884233 0.87 MAPT (0.60) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6879167 0.85 POLB (0.68) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6879163 0.85 POLB (0.68) MAPTPLA2G1BPOLBATG4BBCL2
SCHEMBL6884124 0.84 BCL2L2 (0.66) MAPTPLA2G1BPOLBATG4BBCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673816-B1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Esswein, Angelika (DE) 2004-01-06 US disclosed
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD 2003-02-13 US disclosed
EP-1117655-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS Esswein, Angelika (DE) 2001-07-25 EP disclosed
WO-2000018747-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders NR1H4, NR1D1, NR1I2 MAPT 3886/4885PLA2G1B 3423/4885POLB 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.